NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing nanomedicines for antiviral therapy, will present at the NIBA 153rd Investment Conference on October 7, 2026, in Fort Lauderdale, Florida. The announcement comes as the company advances its lead drug candidate, NV-387, a broad-spectrum antiviral currently in separate Phase 2 clinical trials in the Democratic Republic of Congo for Ebola Bundibugyo virus disease and Mpox. The presentation offers investors and industry stakeholders an opportunity to learn about NanoViricides' progress and its potential to address multiple high-consequence viral threats.
The importance of this announcement lies in the company's innovative approach to antiviral development. NV-387 is designed to target a wide range of viruses, and its ongoing Phase 2 trials for Ebola and Mpox represent critical steps toward validating the technology. If successful, NV-387 could become a key tool in managing outbreaks of these deadly diseases, for which treatment options are currently limited. Moreover, NanoViricides is planning clinical trials of NV-387 for measles, for which the drug has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA). These designations underscore the unmet medical need and provide incentives for development. The company also plans to test NV-387 against viral acute respiratory infections, a category that includes influenza, COVID-19, and RSV, potentially addressing a broad public health burden.
Beyond NV-387, NanoViricides' pipeline includes NV-HHV-1 for herpesviridae viruses and NV-HIV-1 for HIV/AIDS, demonstrating a commitment to tackling chronic viral infections. The company's business model is based on licensing technology from TheraCour Pharma, Inc., and it holds broad, exclusive licenses for several antiviral fields. This strategic foundation, established in 2005, positions NanoViricides to pursue multiple indications while managing risk. For investors, the NIBA conference presentation could provide visibility into upcoming milestones, including the planned clinical trials for measles and respiratory infections. The company's focus on advancing NV-387 into Phase II human clinical trials signals a pivotal phase of growth.
For those following the company, the latest news and updates relating to NNVC are available in its newsroom at https://ibn.fm/NNVC. The full press release can be viewed at https://ibn.fm/vQCM4, and more information about NanoViricides is at www.nanoviricides.com. The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio and offers services such as editorial syndication to 5,000+ outlets and social media distribution. As with any drug development, there are risks, and the company notes that there can be no assurance that its candidates will show sufficient effectiveness and safety for human clinical development.
